

Monika Podhorecka

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2135136/publications.pdf>

Version: 2024-02-01

45
papers

960
citations

758635

12
h-index

454577

30
g-index

49
all docs

49
docs citations

49
times ranked

2059
citing authors

#	ARTICLE	IF	CITATIONS
1	Metformin - its anti-cancer effects in hematologic malignancies. <i>Oncology Reviews</i> , 2021, 15, 514.	0.8	14
2	Therapeutic Options for Patients with TP53 Deficient Chronic Lymphocytic Leukemia: Narrative Review. <i>Cancer Management and Research</i> , 2021, Volume 13, 1459-1476.	0.9	3
3	Prognostic significance of isochromosome 17q in hematologic malignancies. <i>Oncotarget</i> , 2021, 12, 708-718.	0.8	3
4	Outcome of a Real-Life Population of Patients With Acute Promyelocytic Leukemia Treated According to the PETHEMA Guidelines: The Polish Adult Leukemia Group (PALG) Experience. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2020, 20, 105-113.	0.2	3
5	<p>The Neutrophil to Lymphocyte and Lymphocyte to Monocyte Ratios as New Prognostic Factors in Hematological Malignancies – Narrative Review</p>. <i>Cancer Management and Research</i> , 2020, Volume 12, 2961-2977.	0.9	52
6	Pierwotne chł&oniki nadnerczy jako interdyscyplinarny problem endokrynologiczny i hematologiczny – praktyczne wskaz&onki w zakresie diagnostyki i leczenia. <i>Hematologia</i> , 2020, 11, 125-165.	0.0	0
7	<p>Assessment of microRNA expression in leukemic cells as predictors of sensitivity to purine nucleoside analogs, fludarabine and cladribine, in chronic lymphocytic leukemia patients</p>. <i>Cancer Management and Research</i> , 2019, Volume 11, 5021-5031.	0.9	6
8	Intraventricular treatment of secondary central nervous system lymphoma – Case study and literature overview. <i>Neurologia I Neurochirurgia Polska</i> , 2018, 52, 410-414.	0.6	1
9	Central nervous involvement by chronic lymphocytic leukaemia. <i>Neurologia I Neurochirurgia Polska</i> , 2018, 52, 228-234.	0.6	3
10	Abnormal microRNA expression in the course of hematological malignancies. <i>Cancer Management and Research</i> , 2018, Volume 10, 4267-4277.	0.9	32
11	Assessment of micro RNAs expression in leukemic cells as prognostic markers in chronic lymphocytic leukemia: micro RNAs can predict survival in a course of the disease. <i>Oncotarget</i> , 2018, 9, 19136-19146.	0.8	5
12	Neutropenia in adults – significant diagnostic issue. <i>Pielęgniarstwo XXI Wieku</i> , 2018, 17, 37-43.	0.2	0
13	Zesp&on&on, hemofagocytowy indukowany terapi&on... hormonaln&on... – studium przypadku klinicznego. <i>Acta Haematologica Polonica</i> , 2018, 49, 151-156.	0.1	0
14	DNA Damage Response Resulting from Replication Stress Induced by Synchronization of Cells by Inhibitors of DNA Replication: Analysis by Flow Cytometry. <i>Methods in Molecular Biology</i> , 2017, 1524, 107-119.	0.4	8
15	Changes in T-cell subpopulations and cytokine network during early period of ibrutinib therapy in chronic lymphocytic leukemia patients: the significant decrease in T regulatory cells number. <i>Oncotarget</i> , 2017, 8, 34661-34669.	0.8	28
16	Metformin – its potential anti-cancer and anti-aging effects. <i>Postepy Higieny I Medycyny Doswiadczalnej</i> , 2017, 71, 0-0.	0.1	108
17	Metformina: stary lek w nowej aplikacji. <i>Acta Haematologica Polonica</i> , 2016, 47, 139-145.	0.1	1
18	Danazol induces apoptosis and cytotoxicity of leukemic cells alone and in combination with purine nucleoside analogs in chronic lymphocytic leukemia. <i>Annals of Hematology</i> , 2016, 95, 425-435.	0.8	7

#	ARTICLE	IF	CITATIONS
19	Assessment of red blood cell distribution width as a prognostic marker in chronic lymphocytic leukemia. <i>Oncotarget</i> , 2016, 7, 32846-32853.	0.8	44
20	Deregulation of Apoptosis - Is it Still an Important Issue in Pathogenesis of Chronic Lymphocytic Leukemia?. <i>Current Cancer Drug Targets</i> , 2016, 16, 652-658.	0.8	3
21	Advances in hematology – research that revolutionized patient care. <i>Zdrowie Publiczne</i> , 2015, 125, 32-35.	0.2	0
22	The rate of in vitro fludarabine-induced peripheral blood and bone marrow cell apoptosis may predict the chemotherapy outcome in patients with chronic lymphocytic leukemia. <i>European Journal of Clinical Pharmacology</i> , 2015, 71, 1121-1127.	0.8	2
23	Target Therapy in Hematological Malignancies: New Monoclonal Antibodies. <i>International Scholarly Research Notices</i> , 2014, 2014, 1-16.	0.9	6
24	Bullous pyoderma gangrenosum associated with pancytopenia of unknown origin. <i>Postepy Dermatologii i Alergologii</i> , 2014, 4, 272-276.	0.4	6
25	Danazol – możliwości wykorzystania w leczeniu chorób hematologicznych. <i>Acta Haematologica Polonica</i> , 2014, 45, 184-189.	0.1	0
26	Deleterious effects of traditional Chinese medicine preparations on the course of psoriasis—a case report. <i>Annals of Agricultural and Environmental Medicine</i> , 2013, 20, 816-8.	0.5	4
27	Editorial (Hot Topic: The Importance of Rational Chemotherapy of Chronic Lymphocytic Leukemia). <i>Current Pharmaceutical Design</i> , 2012, 18, 3321-3322.	0.9	0
28	Resveratrol increases rate of apoptosis caused by purine analogues in malignant lymphocytes of chronic lymphocytic leukemia. <i>Annals of Hematology</i> , 2011, 90, 173-183.	0.8	35
29	Cell Synchronization by Inhibitors of DNA Replication Induces Replication Stress and DNA Damage Response: Analysis by Flow Cytometry. <i>Methods in Molecular Biology</i> , 2011, 761, 85-96.	0.4	33
30	Simvastatin and purine analogs have a synergic effect on apoptosis of chronic lymphocytic leukemia cells. <i>Annals of Hematology</i> , 2010, 89, 1115-1124.	0.8	30
31	H2AX Phosphorylation: Its Role in DNA Damage Response and Cancer Therapy. <i>Journal of Nucleic Acids</i> , 2010, 2010, 1-9.	0.8	393
32	Assessment of Peripheral Blood and Bone Marrow Cells Apoptosis Caused by Purine Analogues in Patients with Chronic Lymphocytic Leukemia in Correlation with Parameters of Disease Progression. <i>Acta Haematologica</i> , 2010, 123, 171-178.	0.7	2
33	Cytometric detection of chromatin relaxation, an early reporter of DNA damage response. <i>Cell Cycle</i> , 2009, 8, 2233-2237.	1.3	22
34	Thalidomide induces phosphorylation of histone H2AX and increases rate of apoptosis caused by fludarabine in malignant lymphocytes of chronic lymphocytic leukemia in short-term cell cultures. <i>Leukemia Research</i> , 2009, 33, 997-1000.	0.4	5
35	Intracellular Cytokine Expression by T Cells Differs in ZAP-70-Positive and ZAP-70-Negative Chronic Lymphocytic Leukaemia Patients. <i>Acta Haematologica</i> , 2007, 118, 106-110.	0.7	0
36	Lovastatin and thalidomide have a combined effect on the rate of multiple myeloma cell apoptosis in short term cell cultures. <i>European Journal of Clinical Pharmacology</i> , 2006, 62, 325-329.	0.8	12

#	ARTICLE	IF	CITATIONS
37	High Frequency of T Regulatory Cells in Patients with B-Cell Chronic Lymphocytic Leukemia (B-CLL) Is Decreased by Thalidomide and Fludarabine Treatment.. Blood, 2006, 108, 2108-2108.	0.6	0
38	Clinical Efficacy and Safety of Combined Thalidomide and Fludarabine Therapy in B-Cell Chronic Lymphocytic Leukemia Patients.. Blood, 2006, 108, 4975-4975.	0.6	0
39	Lovastatin and Thalidomide Have an Synergic Effect on the Rate of Multiple Myeloma Cell Apoptosis in Short Term Cell Cultures.. Blood, 2005, 106, 5121-5121.	0.6	0
40	Intracellular IFN- γ expression by CD3+/CD8+ cell subset in B-CLL patients correlates with stage of the disease. European Journal of Haematology, 2004, 73, 29-35.	1.1	15
41	ZAP-70 Versus CD38 Expression as the Prognostic Factors in B-Cell Chronic Lymphocytic Leukemia.. Blood, 2004, 104, 4780-4780.	0.6	0
42	Influence of lovastatin on BCL-2 and BAX expression by plasma cells and T lymphocytes in short-term cultures of multiple myeloma bone marrow mononuclear cells. Polish Journal of Pharmacology, 2004, 56, 485-9.	0.3	6
43	T type 1/type 2 subsets balance in B-cell chronic lymphocytic leukemia—the three-color flow cytometry analysis. Leukemia Research, 2002, 26, 657-660.	0.4	66
44	Short Communication: Expression of Apoptosis Regulating Factors on T Lymphocytes in Multiple Myeloma Patients. Hematology, 2001, 6, 393-397.	0.7	0
45	Assessment of Apoptosis Regulating Factors BCL-2 and Fas Antigens on Malignant and Normal Plasma Cells. Hematology, 2001, 6, 255-260.	0.7	0